Article Figures & Data
Tables
- Table 1.
Characteristics of the pregnancies in the study by serologic findings throughout pregnancy.
Characteristics Normal Complement (%) Low Complement (%) Negative Anti-dsDNA (%) Positive Anti-dsDNA (%) No. pregnancies 127 (48) 136 (52) 150 (57) 114 (43) Ethnicity White 78 (61) 79 (58) 99 (66) 59 (52) African American 47 (37) 50 (37) 47 (31) 50 (44) Maternal age, yrs, mean (SD) 29.5 (5.5) 29.9 (5.3) 30.0 (5.5) 29.3 (5.2) High SLE clinical activity in pregnancy (PEA ≥ 2) 26 (20) 32 (24) 26 (17) 32 (28)* History of renal disease by ACR criteria 41 (32) 65 (48)* 53 (35) 54 (47) Proteinuria (> 500 mg/24 h) during pregnancy 26 (21) 42 (31) 25 (17) 43 (38)** Maximum proteinuria during pregnancy 3.8 g ± 4.4 g 3.5 g ± 5.0 g 2.3 g ± 2.6 g 4.2 g ± 5.5 g SLE rash in pregnancy 23 (18) 45 (33)* 37 (25) 32 (28) SLE arthritis in pregnancy 22 (17) 31 (23) 22 (15) 31 (27)* Any prednisone use in pregnancy 74 (58) 107 (79)* 87 (58) 95 (83)** Prednisone dose > 20 mg in pregnancy 29 (23) 59 (43)* 36 (24) 52 (46)* HCQ use No HCQ in pregnancy 84 (66) 90 (66) 106 (71) 69 (61) HCQ all pregnancy 28 (22) 27 (20) 31 (21) 24 (21) Stopped HCQ for pregnancy 12 (10) 16 (12) 11 (7) 17 (15)* Azathioprine use in pregnancy 10 (8) 20 (15) 12 (8) 19 (17) Antiphospholipid syndrome 10 (8) 16 (12) 10 (7) 16 (14) Low complement — — 48 (32) 88 (77)** Positive anti-dsDNA 26 (20) 88 (65)** — — - Table 2.
Pregnancy outcomes by SLE clinical disease activity and complement based on measurements made during each trimester. Only women observed during the trimester of pregnancy under study were included in each group.
Low-activity SLE High-activity SLE p Normal C3/C4 (%) Low C3/C4 (%) Normal C3/C4 (%) Low C3/C4 (%) Compares All 4 Groups Compares Low and High Activity Compares Low and Normal Complement First trimester N 84 68 4 8 Fetal loss 12 (14) 10 (15) 1 (25) 4 (50) 0.57 0.05 0.55 Preterm* 25 (35) 27 (47) 1 (33) 3 (75) Too few** Too few** 0.11 SGA† 13 (18) 7 (12) 1 (33) 2 (50) Too few** Too few** 0.50 Second trimester N 118 76 13 16 Fetal loss 7 (6) 7 (9) 0 (0) 6 (38) 0.05 0.019 0.021 Preterm* 36 (32) 26 (38) 9 (69) 9 (90) 0.004 0.0003 0.27 SGA† 25 (23) 12 (17) 8 (23) 1 (10) 0.59 0.71 0.31 Third trimester N 112 71 17 13 Fetal loss 0 1 (1) 2 (12) 1 (8) Too few** Too few** Too few** Preterm* 39 (35) 27 (39) 7 (47) 8 (67) 0.24 0.059 0.35 SGA† 27 (25) 12 (17) 5 (35) 3 (25) 0.55 0.36 0.26 - Table 3.
Pregnancy outcomes by SLE clinical disease activity and presence of the anti-dsDNA antibody, based on measurements made at each trimester. Only women observed during the trimester of pregnancy under study were included in each group.
Low-activity SLE High-activity SLE p Anti-dsDNA Absent (%) Anti-dsDNA Present (%) Anti-dsDNA Absent (%) Anti-dsDNA Present (%) Compares All 4 Groups Compares Low and High Activity Compares with/without Anti-dsDNA First trimester N 92 61 3 9 Fetal loss 12 (13) 10 (16) 1 (33) 4 (44) 0.46 0.049 0.29 Preterm* 30 (38) 22 (43) 0 4 (80) Too few** Too few** 0.27 SGA† 12 (15) 8 (16) 1 (50) 2 (40) Too few** Too few** 0.77 Second trimester N 131 63 13 16 Fetal loss 6 (5) 8 (13) 3 (23) 3 (19) 0.11 0.019 0.039 Preterm* 39 (31) 23 (42) 7 (70) 11 (85) 0.0029 0.0003 0.032 SGA† 25 (20) 12 (22) 2 (20) 2 (15) 0.96 0.71 0.94 Third trimester N 121 62 21 9 Fetal loss 1 (1) 0 (0) 3 (14) 0 (0) Too few** Too few** Too few** Preterm* 40 (33) 26 (42) 11 (61) 4 (44) 0.17 0.061 0.45 SGA† 24 (20) 15 (24) 8 (44) 0 (0) 0.18 0.36 0.69
In this issue
The Clinical Utility of Measuring Complement and Anti-dsDNA Antibodies During Pregnancy in Patients with Systemic Lupus Erythematosus
